Bayer receives FDA approval for first-line lung cancer therapy HYRNUO

Bayer has received FDA approval for HYRNUO as a first-line therapy for lung cancer, marking a regulatory milestone for treatment options in this disease area in the United States.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 9 Sep 2026 and 10 Sep 2026.